The association of gut microbiome with recurrent pregnancy loss: A comprehensive review.

IF 1.9 Q3 PHARMACOLOGY & PHARMACY
Drug Discoveries and Therapeutics Pub Date : 2023-07-12 Epub Date: 2023-06-25 DOI:10.5582/ddt.2023.01010
Jun Zhu, Jiaxi Jin, Qing Qi, Lisha Li, Jing Zhou, Liwen Cao, Ling Wang
{"title":"The association of gut microbiome with recurrent pregnancy loss: A comprehensive review.","authors":"Jun Zhu, Jiaxi Jin, Qing Qi, Lisha Li, Jing Zhou, Liwen Cao, Ling Wang","doi":"10.5582/ddt.2023.01010","DOIUrl":null,"url":null,"abstract":"<p><p>The steady-state gut microbiome not only promotes the metabolism and absorption of nutrients that are difficult to digest by the host itself, but also participates in systemic metabolism. Once the dynamic balance is disturbed, the gut microbiome may lead to a variety of diseases. Recurrent pregnancy loss (RPL) affects 1-2% of women of reproductive age, and its prevalence has increased in recent years. According to the literature review, the gut microbiome is a new potential driver of the pathophysiology of recurrent abortion, and the gut microbiome has emerged as a new candidate for clinical prevention and treatment of RPL. However, few studies have concentrated on the direct correlation between RPL and the gut microbiome, and the mechanisms by which the gut microbiome influences recurrent miscarriage need further investigation. In this review, the effects of the gut microbiome on RPL were discussed and found to be associated with inflammatory response, the disruption of insulin signaling pathway and the formation of insulin resistance, maintenance of immunological tolerance at the maternal-fetal interface due to the interference with the immune imbalance of Treg/Th17 cells, and obesity.</p>","PeriodicalId":47494,"journal":{"name":"Drug Discoveries and Therapeutics","volume":"17 3","pages":"157-169"},"PeriodicalIF":1.9000,"publicationDate":"2023-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Discoveries and Therapeutics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5582/ddt.2023.01010","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/6/25 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

The steady-state gut microbiome not only promotes the metabolism and absorption of nutrients that are difficult to digest by the host itself, but also participates in systemic metabolism. Once the dynamic balance is disturbed, the gut microbiome may lead to a variety of diseases. Recurrent pregnancy loss (RPL) affects 1-2% of women of reproductive age, and its prevalence has increased in recent years. According to the literature review, the gut microbiome is a new potential driver of the pathophysiology of recurrent abortion, and the gut microbiome has emerged as a new candidate for clinical prevention and treatment of RPL. However, few studies have concentrated on the direct correlation between RPL and the gut microbiome, and the mechanisms by which the gut microbiome influences recurrent miscarriage need further investigation. In this review, the effects of the gut microbiome on RPL were discussed and found to be associated with inflammatory response, the disruption of insulin signaling pathway and the formation of insulin resistance, maintenance of immunological tolerance at the maternal-fetal interface due to the interference with the immune imbalance of Treg/Th17 cells, and obesity.

肠道微生物组与复发性妊娠失败的关系:综述。
稳态肠道微生物群不仅能促进宿主自身难以消化的营养物质的代谢和吸收,还能参与全身代谢。一旦动态平衡被打破,肠道微生物群可能会导致各种疾病。复发性妊娠失败(RPL)影响到 1%-2%的育龄妇女,近年来其发病率有所上升。根据文献综述,肠道微生物组是复发性流产病理生理学的一个新的潜在驱动因素,肠道微生物组已成为临床预防和治疗 RPL 的新候选者。然而,很少有研究集中于 RPL 与肠道微生物组之间的直接相关性,肠道微生物组影响复发性流产的机制还需要进一步研究。本综述讨论了肠道微生物组对 RPL 的影响,发现肠道微生物组与炎症反应、胰岛素信号通路的破坏和胰岛素抵抗的形成、Treg/Th17 细胞免疫失衡导致的母胎界面免疫耐受的维持以及肥胖有关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Drug Discoveries and Therapeutics
Drug Discoveries and Therapeutics PHARMACOLOGY & PHARMACY-
CiteScore
3.20
自引率
3.20%
发文量
51
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信